$EDIT News

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift

Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia

Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target

Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?

Editas: Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Files Prospectus For Offering $400M Mixed Shelf

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Editas Medicine (NASDAQ:EDIT) Beats Q2 Estimates, but One-Time Revenue Boost Masks Underlying Momentum

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.